Press releaseBusiness Wire
CEL-SCI
CVM · NYSE American
$1.55−$0.10 (−6.06%)TodayMarket closed ·
Prev close $1.65
Latest news
- Press releaseBusiness Wire
CEL-SCI Reports Fiscal Third Quarter 2026 Results
- Press releaseBusiness Wire
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
- Press releaseBusiness Wire
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseBusiness Wire
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
- Press releaseBusiness Wire
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
- Press releaseBusiness Wire
CEL-SCI Announces Closing of Offering
- News
CEL-SCI Announces Dual-Track Strategy To Bring Multikine To Patients With Head And Neck Cancer Through Parallel Regulatory Pathways In The U.S. And Saudi Arabia
- Press releaseBusiness Wire
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
- Press releaseBusiness Wire
CEL-SCI Corporation Announces Pricing of Offering
- Press releaseBusiness Wire
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
- Press releaseBusiness Wire
CEL-SCI Reports Fiscal Second Quarter 2026 Results
- Press releaseBusiness Wire
CEL-SCI Announces Closing of Public Offering
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
CEL-SCI Corporation Announces Pricing of Public Offering
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseBusiness Wire
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseBusiness Wire
CEL-SCI Reports Fiscal First Quarter 2026 Results
- Press releaseBusiness Wire
CEL-SCI Reports Fiscal 2025 Results
- Press releaseBusiness Wire
CEL-SCI Announces Closing of $10 Million Public Offering
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsRishabh Mishra
Stock Market Today: Nvidia Drags Down Nasdaq Futures, Dow Trades Higher—Dollar General, Dell, Best Buy In Focus (UPDATED)
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
CEL-SCI Announces Pricing of $10 Million Public Offering
- Press releaseBusiness Wire
CEL-SCI Announces Proposed Public Offering
- Press releaseBusiness Wire
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
- Press releaseBusiness Wire
CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
- Press releaseBusiness Wire
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
- Press releaseBusiness Wire
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
- Press releaseBusiness Wire
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.